OXYVEN
OXYVEN is a medical device designed for intravenous oxygen therapy, a method used for several decades in integrative and functional medicine to support circulation, cellular metabolism, and regeneration processes. OXYVEN therapy consists of the controlled administration of very small quantities of medical oxygen directly into the venous bloodstream, under strict medical supervision.
The device is designed to ensure precise flow control and maximum patient safety. It is used as an adjunctive therapy for chronic, degenerative, and vascular conditions.
How does the OXYVEN device work?
The OXYVEN device introduces extremely small quantities of medical oxygen slowly and in a controlled manner directly into a peripheral vein. This gradual oxygen delivery acts as a biological stimulus, prompting the body to activate compensatory and adaptive mechanisms.
This mechanism stimulates:
▪️ peripheral microcirculation
▪️ oxygen utilisation at the cellular level
▪️ activation of antioxidant enzymes
▪️ regulation of oxidative stress
▪️ mitochondrial function
The purpose of the therapy is not to increase oxygen saturation directly but to trigger beneficial physiological responses through controlled oxidative stress.
OXYVEN specifications / functions / technologies
▪️ device specifically designed for intravenous oxygen therapy
▪️ precise control of oxygen flow
▪️ slow and safe administration
▪️ compatible with medical-grade oxygen
▪️ used exclusively under medical supervision
▪️ system designed for repeated therapy sessions
▪️ technology used in functional and integrative medicine
Methods of use
OXYVEN therapy is performed under controlled medical conditions.
▪️ oxygen is administered intravenously through a peripheral venous catheter
▪️ the flow rate is individually adapted according to the patient’s condition
▪️ a session generally lasts between 20 and 40 minutes
▪️ treatment is administered as a course comprising several consecutive sessions
▪️ the patient remains in a relaxed position under continuous monitoring
▪️ See INTRAVENOUS OXYGEN THERAPY
What advantages and benefits does the OXYVEN device provide?
Advantages
▪️ minimally invasive therapeutic method
▪️ natural physiological stimulation of the body
▪️ can be combined with other intravenous therapies
▪️ well tolerated by most patients
▪️ applicable to a wide range of chronic conditions
Benefits
▪️ improved peripheral microcirculation
▪️ support for cellular metabolism
▪️ reduction of oxidative stress
▪️ optimisation of mitochondrial function
▪️ support in degenerative conditions
▪️ support for vascular and neurological functions
▪️ increased adaptive capacity of the body
Medical device classification
The OXYVEN device is classified as a Class IIb medical device under the European Medical Device Regulation (EU) 2017/745 (MDR).
This classification is based on the fact that OXYVEN is an active device intended for the controlled intravenous administration of medical oxygen, involving direct interaction with the circulatory system and short-term invasive use, exclusively under medical supervision.
Its Class IIb classification certifies that the device is intended for clinical use as an adjunctive therapy and requires a high level of safety, performance, and risk control, in compliance with strict clinical evaluation and MDR conformity requirements.
Clinical studies and scientific evidence
1. Effectiveness of OXYVEN therapy in age-related macular degeneration (AMD)
A clinical study involving 44 patients with dry age-related macular degeneration—the most common and progressive form of AMD—evaluated the effects of intravenous oxygen therapy administered using OXYVEN-type devices.
Study results:
▪️ after three weeks of treatment, mean visual acuity increased from 34.5% to 43.2%
▪️ the improvement was partially maintained at the four-month follow-up assessment
▪️ the therapy proved most effective in patients with an initial visual acuity above 10%
▪️ in 86% of cases, an improvement in vision of at least 10% was observed in one eye
Proposed mechanism of action:
▪️ reduction of oxidative stress in the macula
▪️ improvement of local microcirculation
▪️ optimisation of oxygen and nutrient delivery to retinal tissue
These results support the use of intravenous oxygen therapy as an adjunctive option in the management of age-related macular degeneration.
Link: https://pubmed.ncbi.nlm.nih.gov/15541506/
2. Intravenous oxygen and its effects on microcirculation and oxidative stress
Title: Effects of Intravenous Oxygen Administration on Microcirculation and Oxidative Stress
Summary: A review describing the physiological mechanisms triggered by the slow intravenous administration of low-dose oxygen. The authors highlight the stimulation of peripheral microcirculation, activation of endogenous antioxidant systems, and regulation of oxidative stress without directly increasing systemic oxygen saturation. These effects support the use of this method as an adaptive biological stimulus in chronic and degenerative conditions.
Link: https://pubmed.ncbi.nlm.nih.gov/18426374/
3. The role of oxygen therapy in functional and integrative medicine
Title: Oxygen-Based Therapies in Integrative Medicine: Mechanisms and Clinical Perspectives
Summary: A review article analysing the use of oxygen-based therapies in functional and integrative medicine, including intravenous oxygen therapy. The study highlights their positive impact on mitochondrial function, cellular metabolism, and the body’s capacity to adapt to stress, emphasising the role of these therapies as adjunctive options in chronic, vascular, and degenerative conditions.
Link: https://pubmed.ncbi.nlm.nih.gov/30784632/
4. Safety of controlled intravenous oxygen administration
Title: Safety Considerations of Low-Dose Intravenous Oxygen Therapy
Summary: A paper evaluating the safety profile of administering very small doses of oxygen intravenously under medical monitoring. The results indicate that the therapy is well tolerated when slow-flow protocols and appropriate patient-selection criteria are followed, supporting the use of dedicated devices such as OXYVEN under controlled clinical conditions.
Link: https://pubmed.ncbi.nlm.nih.gov/26686862/